Interleukin 23 Inhibitor

Aka: Interleukin 23 Inhibitor, IL-23 Monclonal Antibody, IL23 Inhibitor, Interleukin-23, IL-23, Guselkumab, Tremfya, Risankizumab, Skyrizi, Tildrakizumab, Ilumya

advertisement

II. Indications: FDA Approved

  1. Plaque Psoriasis (moderate to severe, candidates for systemic therapy or Phototherapy)
    1. Guselkumab (Tremfya)
    2. Risankizumab (Skyrizi)
    3. Tildrakizumab (Ilumya)
  2. Active Psoriatic Arthritis
    1. Guselkumab (Tremfya)
    2. Risankizumab (Skyrizi)
  3. Crohn's Disease (adults with moderate to severe active disease)
    1. Risankizumab (Skyrizi)

III. Mechanism

  1. Interleukin 23 Inhibitor (IL23 Inhibitor)
    1. The Cytokines IL-23 and IL-17 are released from activated myeloid Dendritic Cells and Macrophages
    2. Cytokines (e.g. IL-23) trigger a proinflammatory cascade, activating immune cells (e.g. T cells)
      1. Angiogenesis
      2. Keratinocyte proliferation
      3. Immune cells migrate to within psoriatic lesions
  2. IL23 Monoclonal antibodies
    1. Self-injectable agents that target IL23
    2. Suppress IL23-triggered inflammatory response

IV. Medications

  1. Guselkumab (Tremfya)
    1. Plaque Psoriasis or Psoriatic Arthritis (Adults): 100 mg SQ at Week 0, Week 4 and then every 8 weeks
  2. Risankizumab (Skyrizi)
    1. Plaque Psoriasis or Psoriatic Arthritis (Adults): 150 mg SQ at Week 0, Week 4, then every 12 weeks
    2. Crohn's Disease (Adults)
      1. IV Induction Start: 600 mg IV infusion over 1 hour at week 0, week 4 and week 8
      2. SQ Maintenance (follows IV course): 180 mg or 360 mg SQ at week 12, then every 8 weeks
      3. Monitor for hepatotoxicity at least during IV induction course at baseline and periodically in first 12 weeks
  3. Tildrakizumab (Ilumya)
    1. Plaque Psoriasis (Adults): 100 mg SQ at Week 0 and Week 4, and then every 12 weeks

V. Adverse Effects

  1. Serious
    1. Hypersensitivity Reaction (including Anaphylaxis)
    2. Serious Infections
    3. Tuberculosis activation
      1. Test for Tuberculosis before initiating agents
  2. Common
    1. Infections (URI, UTI, dermatophyte fungal infections, HSV)
    2. Headache
    3. Arthralgias
    4. Gastroenteritis (including Diarrhea)

VI. Safety

  1. Unknown safety in pregnancy
  2. Unknown safety in Lactation

VII. Drug Interactions

  1. Live Vaccines
    1. Avoid concurrently with IL-23 inhibitors

VIII. Resources

  1. Guselkumab (DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e6dc9ae-1c4c-42d9-87aa-c315ecc51b56
  2. Risankizumab (DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7148c8eb-b39e-e20a-6494-a6df82392858
  3. Tildrakizumab (DailyMed)
    1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6a322bb-51b9-4f0e-8642-62a9682ffcde

Images: Related links to external sites (from Bing)

These images are a random sampling from a Bing search on the term "Interleukin 23 Inhibitor." Click on the image (or right click) to open the source website in a new browser window. Search Bing for all related images

Related Studies

Cost: Medications

tremfya (on 11/23/2022 at Medicaid.Gov Survey of pharmacy drug pricing)
TREMFYA 100 MG/ML INJECTOR $12,239.52 per ml
skyrizi (on 7/20/2022 at Medicaid.Gov Survey of pharmacy drug pricing)
SKYRIZI 150 MG/ML PEN $17,642.38 per ml
SKYRIZI 150 MG/ML SYRINGE $17,835.55 per ml
FPNotebook does not benefit financially from showing this medication data or their pharmacy links. This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See Needy Meds for financial assistance information. GoodRx is another tool for finding lower drug prices.

Related Topics in Pharmacology

advertisement